News & Updates
Filter by Specialty:
Niraparib maintenance boosts PFS in advanced ovarian cancer
Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.
Niraparib maintenance boosts PFS in advanced ovarian cancer
05 Oct 2022
PLD-apatinib combo show promise for ovarian cancer
A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.
PLD-apatinib combo show promise for ovarian cancer
03 Oct 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Does frozen embryo transfer up hypertension risk during pregnancy?
The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.
